During the past decades, the availability of HER2-targeted therapy including trastuzumab [4, 5], lapatinib [6, 7], pertuzumab [8–10], and trastuzumab emtansine [11, 12] have significantly improved the outcomes of HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.